PricewaterhouseCoopers
Difficult VC Funding Market Extends to 'Omics, MDx
NEW YORK (GenomeWeb News) – Venture capital investing into the 'omics-related and molecular diagnostics space remains challenging and is unlikely to improve in the near-term, according to some VC fund managers.
VC Funding in Life Sciences Plummets in Q2, Report Finds
NEW YORK (GenomeWeb News) – Venture capital investments into the life sciences dropped sharply in the second quarter compared to a year ago, according to a report this week from PricewaterhouseCoopers and the National Venture Capital Association.
PwC Survey Finds Dissatisfaction Among Drug, Device Makers About FDA's Personalized Rx Efforts
Premium
The survey revealed that only 8 percent of drug and device makers feel the FDA "is doing enough to advance personalized medicine." Moreover, 56 percent of respondents familiar with FDA's Critical Path Initiative said that the agency "lacks the capability to implement the initiative," which aims to bring innovative drugs to market.
PwC Report Finds FDA Needs Resources, Communication
A PriceWaterhouseCoopers survey of small life sciences and pharma firms found mixed opinions on FDA's efforts to advance personalized medicine and biomarkers.
According to one of the world's largest professional services firms, the trend toward tailoring drugs based on clinical factors and genomic variation will create opportunities and challenges for the pharmaceutical and biotech industries. PricewaterhouseCoopers estimates that the market for "a more personalized approach to health and wellness will grow to as much as $452 billion by 2015."
Jul 24, 2009
Feb 2, 2009
Jan 26, 2009